SAN DIEGO, Aug. 18 /PRNewswire-FirstCall/ — Aethlon Medical,
Inc. (OTC Bulletin Board:
AEMD), the pioneer in developing therapeutic filtration devices
to address infectious disease and cancer, today announced that it
has entered into an agreement with GVK Biosciences (GVK BIO) to
expand the opportunity for Aethlon to commercialize its
Hemopurifier® treatment technology at three to five new
clinical centers in India. The therapeutic focus at each
center will be the implementation of the Hemopurifier® as an
adjunct therapy to accelerate the benefit of HCV standard of care
(SOC) drug regimens. Therapeutic filtration at the outset of SOC
improves early virus reduction kinetics to levels associated with
patients most likely to achieve a sustained viral response, which
is the goal of HCV therapy. GVK BIO is Asia’s leading
Discovery Research and Development organization.
(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
(Photo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)
Aethlon further disclosed that the Ethics Review Board (ERB) at
Medanta, The Medicity Institute (Medicity) met on August 14th, 2010
to discuss the potential approval for Aethlon to initiate HCV
treatment programs at the Medicity. Aethlon has been advised that a
formal response should be expected from the Medicity ERB in the
coming weeks. The Medicity is a $360 million facility recently
established on a 43-acre campus to be a premier center of medical
tourism in India.
About GVK BiosciencesGVK Biosciences (GVK BIO) is Asia’s
leading Discovery Research and Development organization. GVK BIO
provides a broad spectrum of services, stand-alone and integrated,
across the R&D value chain.
‘/>”/>
